The lung cancer drugs market was valued at around $4 billion in 2010 and is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5% from 2015 to 2020
Dallas, TX -- (SBWIRE) -- 01/28/2014 -- The report “Lung Cancer Drugs Market in G7 Countries (2005 - 2020)” analyzes and studies the major market drivers, restraints, and opportunities in North America, and Europe.
Browse market data tables and in-depth Table Of Content on "Lung Cancer Drugs Market".
Early buyers will receive 10% customization on this report @ http://www.marketsandmarkets.com/requestCustomization.asp?id=508
The lung cancer drugs market was valued at around $4 billion in 2010 and is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5% from 2015 to 2020.
Lung cancer is the most common form of cancer in terms of incidence and number of deaths. It is a disease wherein the cell lining of lung tissue grows uncontrollably and leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer that accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers.
According to WHO, lung cancer prevalence is expected to grow in the emerging markets such as the BRIC countries and other Asian and African markets due to an increase in the use of tobacco products. Tobacco is the primary cause of around 80% of all lung cancers. The other causes such as radon gas exposure, asbestos can be causative factor for developing lung cancer.
The U.S. dominates the lung cancer drug market in North America with 93.5% share; whereas Germany dominates the market of Europe with 32.4% share.
Major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca Plc (U.K.), Eli Lilly and Company (U.S.), Sanofi-Aventis (France), Pfizer Inc. (U.S.), GlaxoSmithKline Pharmaceuticals Limited (U.K.), ArQule Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), Agennix AG (Germany), and Boehringer Ingelheim GmbH (Germany).
Browse Related Reports:
Global Lung Cancer Surgery Market (Devices & Treatment Outlook) – Trends & Challenges (2010 – 2015)
Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets